Dacarbazine for leiomyosarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 24 Jan 2023: Trial started, NCT07942168
  2. 17 Nov 2026: Trial registered, NCT07942168

The trials

NCT07942168: Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma

State
Under way
Phase
Phase 2
People
100 planned
Started
24 Jan 2023
Primary completion
Jan 2027
Arms
Doxorubicin+Dacarbazine
Results
None posted
  1. 24 Jan 2023: Trial started
  2. 17 Nov 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Dtic-dome.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.